imgboxbg

News

NMPA Approves IND Application for CT103A, A Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma codeveloped by IASO BIO and Innovent Bio

  • Categories:Press Release
  • Author:
  • Origin:
  • Time of issue:2019-09-11 17:17
  • Views:92

NMPA Approves IND Application for CT103A, A Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma codeveloped by IASO BIO and Innovent Bio

  • Categories:Press Release
  • Author:
  • Origin:
  • Time of issue:2019-09-11 17:17
  • Views:92
Information

September 10th,2019, IASO Biotherapeutics(IASO Bio), a clinical stage biotechnology company advancing the development of innovative therapies for cancer, announced today that the Company has received an Investigational New Drug Application (IND) approval from the National Medical Products Administration (NMPA) for the treatment of relapsed refractory multiple myeloma (rr/mm) patients. 

驯鹿医疗